Used as a key chiral intermediate in the synthesis of antidiabetic drugs, particularly in the production of DPP-4 inhibitors like sitagliptin. Its stereochemistry allows for high selectivity and efficacy in the final active pharmaceutical ingredient. The compound’s fluorinated structure enhances metabolic stability and bioavailability in the resulting drug. Commonly employed in asymmetric synthesis routes due to its well-defined stereocenters and compatibility with enzymatic or catalytic transformations.